CAU
ADMA icon

Caxton Associates (UK)’s ADMA Biologics ADMA Stock Holding History

Caxton Associates (UK)’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$136K Buy
+15,108
New +$238K ﹤0.01% 736
2025
Q3 		– Sell
-33,664
Closed -$613K – 679
2025
Q2 		$613K Hold
33,664
– – 0.02% 379
2025
Q1 		$668K Buy
+33,664
New +$582K 0.02% 413

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Caxton Associates (UK)'s ADMA Position: Q1 2026 in Review

Caxton Associates (UK) opened a new position in ADMA Biologics (ADMA) in Q1 2026: 15,108 shares worth $136K. The stake represents ﹤0.01% of the portfolio and ranks #736 among its holdings. This is a return to the name: Caxton Associates (UK) previously reported a position in ADMA as recently as Q2 2025.

Caxton Associates (UK) first reported a position in ADMA in Q1 2025 and has held it in 3 quarters since. The position peaked at $668K in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Caxton Associates (UK) held 15,108 shares of ADMA Biologics worth $136K as of Q1 2026.
  • ADMA Biologics was a new Caxton Associates (UK) position in Q1 2026.
  • ADMA Biologics made up ﹤0.01% of Caxton Associates (UK)'s portfolio in Q1 2026, its #736 holding.
  • Caxton Associates (UK) first reported a position in ADMA Biologics in Q1 2025 and has held it in 3 quarters since.
  • Caxton Associates (UK)'s ADMA Biologics position peaked at $668K in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.